Lipiodol as an Imaging Biomarker in Patients With Primary and Metastatic Liver Cancer
Status:
Completed
Trial end date:
2020-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the whether Lipiodol can be used as an imaging
biomarker, predicting tumor response to therapy in patients with primary and metastatic liver
cancer. Lipiodol-based transarterial chemoembolization (TACE) has been an accepted standard
of care procedure for unresectable liver lesions for several decades. Lipiodol is used as a
carrier for chemotherapy agents and also as an occlusion agent. In TACE procedures, Lipiodol
is mixed with the chemotherapy agent(s) and delivered to the tumor via the hepatic artery,
causing necrosis of the targeted tumor(s). Response to therapy will be evaluated every 1, 3
and 6 months by clinic visits, MRI/CT/PET scans and blood tests (to include assessment of
liver function and tumor markers).
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Yale University